全文获取类型
收费全文 | 1980篇 |
免费 | 150篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 62篇 |
儿科学 | 55篇 |
妇产科学 | 29篇 |
基础医学 | 366篇 |
口腔科学 | 44篇 |
临床医学 | 177篇 |
内科学 | 328篇 |
皮肤病学 | 36篇 |
神经病学 | 285篇 |
特种医学 | 68篇 |
外科学 | 173篇 |
综合类 | 6篇 |
一般理论 | 2篇 |
预防医学 | 136篇 |
眼科学 | 68篇 |
药学 | 117篇 |
中国医学 | 4篇 |
肿瘤学 | 179篇 |
出版年
2023年 | 20篇 |
2022年 | 27篇 |
2021年 | 43篇 |
2020年 | 45篇 |
2019年 | 37篇 |
2018年 | 48篇 |
2017年 | 35篇 |
2016年 | 60篇 |
2015年 | 68篇 |
2014年 | 78篇 |
2013年 | 101篇 |
2012年 | 161篇 |
2011年 | 151篇 |
2010年 | 99篇 |
2009年 | 108篇 |
2008年 | 146篇 |
2007年 | 137篇 |
2006年 | 127篇 |
2005年 | 125篇 |
2004年 | 97篇 |
2003年 | 104篇 |
2002年 | 95篇 |
2001年 | 19篇 |
2000年 | 23篇 |
1999年 | 19篇 |
1998年 | 26篇 |
1997年 | 17篇 |
1996年 | 10篇 |
1995年 | 11篇 |
1994年 | 10篇 |
1993年 | 9篇 |
1992年 | 5篇 |
1991年 | 5篇 |
1990年 | 7篇 |
1988年 | 7篇 |
1987年 | 4篇 |
1986年 | 3篇 |
1985年 | 6篇 |
1984年 | 4篇 |
1983年 | 2篇 |
1982年 | 4篇 |
1981年 | 2篇 |
1979年 | 2篇 |
1971年 | 2篇 |
1969年 | 2篇 |
1963年 | 2篇 |
1905年 | 6篇 |
1902年 | 1篇 |
1883年 | 1篇 |
1866年 | 2篇 |
排序方式: 共有2135条查询结果,搜索用时 15 毫秒
21.
Frank Wilhelm Alexa Holtkamp Antje Theurer Jacques Darman jr. Gernot Duncker Lutz Wilhelm 《Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft》1999,96(10):640-642
BACKGROUND: Although cataract surgery is highly developed today, there are still problems such as secondary cataract. In polishing the posterior capsule lens, epithelial cells often remain, causing secondary cataracts. Additionally, there are the problems of tissue heating and endothelial cell loss during phacoemulsification by ultrasound. This could be another field for improvement of cataract surgery by using the waterjet. METHODS: After removing the cornea of freshly enucleated porcine bulbs, we used the water jet from 4 to 12 bar. The hit angel on the capsule varied between 45 degrees and 90 degrees. RESULTS: Rupture of the posterior capsule occurred at a mean of 8.5 bar using the jet at 45 degrees and a mean of 8.6 bar using the jet at 90 degrees. CONCLUSION: The waterjet pressure should not be over 4 bar during polishing of the posterior capsule. 相似文献
22.
Antileukotrienes are a relatively new class of anti-asthma drugs that either block leukotriene synthesis (5-lipoxygenase inhibitors) like zileuton, or antagonise the most relevant of their receptors (the cysteinyl leukotriene 1 receptor [CysLT1]) like montelukast, zafirlukast or pranlukast. Hence, their major effect is an anti-inflammatory one. With the exception of pranlukast, the other antileukotrienes have been studied and marketed in the US and Europe for long enough to establish that they are useful drugs in the management of asthma. Their effects, significantly better than placebo, seem more pronounced in subjective measurements (i.e. symptoms scores or quality-of-life tests) than in objective parameters (i.e. forced expiratory volume in 1 second or peak expiratory flow rate). Also, there is some evidence that these drugs work better in some subsets of patients with certain genetic polymorphisms - probably related to their leukotriene metabolism - or patients with certain asthma characteristics. There are a small number of comparative studies only, and with regard to long-term asthma control differences between the agents have not been evaluated. Nevertheless, their overall effect appears comparable with sodium cromoglycate (cromolyn sodium) or theophylline, but significantly less than low-dose inhaled corticosteroids. Antileukotrienes have been shown to have a degree of corticosteroid-sparing effect, but salmeterol appears to perform better as an add-on drug. Montelukast is probably the most useful antileukotriene for continuous treatment of exercise-induced asthma, performing as well as salmeterol without inducing any tolerance. All antileukotrienes are taken orally; their frequency of administration is quite different ranging from four times daily (zileuton) to once daily (montelukast). Antileukotrienes are well tolerated drugs, even though zileuton intake has been related to transitional liver enzyme elevations in some cases. Also Churg-Strauss syndrome (a systemic vasculitis), has been described in small numbers of patients taking CysLT1 antagonists. It is quite probable that this disease appears as a consequence of an 'unmasking' effect when corticosteroid dosages are reduced in patients with severe asthma once CysLT1 antagonists are introduced, but more data are needed to definitely establish the mechanism behind this effect. Overall, however, the benefits of antileukotrienes in the treatment of asthma greatly outweigh their risks. 相似文献
23.
G. Hempel Sebastian Krümpelmann Antje May-Manke Barbara Hohenlöchter Gottfried Blaschke Heribert Jürgens Joachim Boos 《Cancer chemotherapy and pharmacology》1997,40(1):45-50
To contribute to effective and safe outpatient treatment, we investigated the metabolism of trofosfamide (Trofo) after oral
administration. We analyzed Trofo metabolism in 15 patients aged from 3 to 73 years who were treated with 150 or 250 mg/m2 Trofo in combination with etoposide. Serum samples were collected with 13 patients after oral administration, and Trofo and
its dechloroethylated metabolites were quantified by gas chromatography. Urine samples were collected from five patients and
analyzed by same method. Ifosfamide (Ifo) was the main metabolite in serum and urine (AUCTrofo:AUCIfo 1:13), whereas cyclophosphamide (Cyclo) was formed in smaller amounts (AUCIfo:AUCCyclo 18:1). Ifo and Cyclo were further oxidized in the chloroethyl side chains to form 2- and 3-dechloroethylifosfamide in varying
quantities. The urinary excretion of Trofo and its dechloroethylated metabolites amounted to about 10% of the total dose.
Our results confirm former in vitro observations about the metabolism of Trofo. The main side-chain metabolites Ifo and Cyclo
can be further activated by oxidation and formation of their respective phosphoramide mustards. Hence, Trofo is an interesting
agent for oral chemotherapy.
Received 21 July 1996 / Accepted: 11 November 1996 相似文献
24.
The relationship of serum-eosinophil cationic protein and eosinophil count to disease activity in children with bronchial asthma 总被引:1,自引:0,他引:1
25.
Gunter von Minckwitz Sebastian Harder Sascha Hövelmann Elke Jäger Salah-Eddin Al-Batran Sibylle Loibl Akin Atmaca Christian Cimpoiasu Antje Neumann Aklil Abera Alexander Knuth Manfred Kaufmann Dirk Jäger Alexander B Maurer Winfried S Wels 《Breast cancer research : BCR》2005,8(1):1-2
Overcoming dendritic cell (DC) dysfunction is a prerequisite for successful active immunotherapy against breast cancer. CD40 ligand (CD40L), a key molecule in the interface between T-lymphocytes and DCs, seems to be instrumental in achieving that goal. Commenting on our data that CD40L protects circulating DCs from apoptosis induced by breast tumor products, Lenahan and Avigan highlighted the potential of CD40L for immunotherapy. We expand on that argument by pointing to additional findings that CD40L not only rescues genuine DCs but also functionally improves populations of immature antigen-presenting cells that fill the DC compartment in patients with breast cancer. 相似文献
26.
27.
28.
Claudia Günther Kristin Blau Ulrike Förster Antje Viehweg Gottfried Wozel Knut Schäkel 《Experimental dermatology》2013,22(8):535-540
Dermal dendritic cells (DCs) play a central role in the immunopathology of psoriasis. We previously identified slanDCs as pro‐inflammatory TNF‐α, IL‐23‐ and IL‐12‐producing DCs in human blood and as prominent inflammatory dermal TNF‐α secreting and CD11c‐positive DC subset in psoriasis. Here, we ask for the effects of TNF‐α‐inhibition on inflammatory slanDCs in skin and blood of 10 patients with psoriasis during 24 weeks of treatment with etanercept. Treatment with etanercept reduced the frequency of dermal slanDCs but did not induce apoptosis as determined by lack of increased active caspase‐3‐expression. In parallel, we found increased frequencies of slanDCs in blood which expressed lower levels of HLA‐DR. Stimulating slanDCs isolated from the blood of healthy donors in vitro induced a strong production of IL‐1β, IL‐6, IL‐23 and IL‐12p70. This capacity was efficiently reduced in the presence of etanercept, thereby indicating that TNF‐α is an autocrine stimulus for maturation and pro‐inflammatory cytokine production of slanDCs. In vivo, we noticed that treatment with etanercept did reduce the number of dermal slanDCs in parallel to the overall expression of TNF‐α and IL‐23p19. However, successful treatment did not down‐regulated the percentage of dermal slanDCs that stained positive for TNF‐α and IL‐23p19 indicating that remaining slanDCs kept their pro‐inflammatory capacity. This study provides novel insights into the immune regulatory properties of etanercept at the level of inflammatory slanDCs in vivo in skin and blood as well as in vitro. 相似文献
29.
30.